Table 3.
Pharmacogenomic guidelines and implementations at TPP sites.
| Gene-Drug Interaction | Number of Implementing Sites |
|---|---|
| CYP2C19-clopidogrel | 7 |
| TPMT-thiopurines | 6 |
| CYP2C9/VKORC1-warfarin | 4 |
| SLCO1B1-simvastatin | 5 |
| CYP2D6/CYP2C19-TCAs | 2 |
| CYP2D6-codeine | 2 |
| HLA-B-abacavir | 2 |
| CYP2D6-SSRIs | 1 |
| CYP3A5-tacrolimus | 1 |
| IFNL3-ribavirin/interferon | 1 |
| ITPA-ribavirin | 1 |
| GLCC1-budesonide, fluticasone, triamcinolone | 1 |
| CYP3A4-amlodipine, atorvastatin, simvastatin, and lovastatin | 1 |
| HLA-B-allopurinol | 0 |
| HLA-B-carbamazepine | 1 |
| DPYD-5FU/capecitabine | 1 |
| IL28B-pegInteron | 2 |
| HLA-B-phenytoin, fosphenytoin therapy | 1 |
| G6PD-rasburicase, Septra | 1 |
| CFTR-Ivacaftor | 0 |
| UGT1A1-irinotecan | 2 |
| CYP2D6 - tamoxifen | 1 |
| 5-HTT-SSRIs | 1 |
| DRD4-methylphenidate | 1 |
| HTR 2A/2C-clozapine, aripiprazole | 1 |
| NAT2-Isoniazid | 1 |
| OPRM1-Naltrexone | 1 |
Text in bold indicates that CPIC guidelines have been published for the gene-drug(s) interaction. TCAs – tricyclic antidepressants. SSRIs - selective serotonin re-uptake inhibitors.